Stock VITR VITROLIFE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vitrolife AB

Equities

VITR

SE0011205202

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
170 SEK -0.47% Intraday chart for Vitrolife AB -1.73% -12.69%
May. 22 Sweden's Vitrolife Wraps Up Purchase of Software Group eFertility MT
May. 22 Vitrolife AB (OM:VITR) acquired Stb Zorg B.V. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 21,439 23,425 75,821 25,210 26,361 23,125 - -
Enterprise Value (EV) 1 20,825 22,514 77,673 26,857 27,589 23,689 22,976 22,310
P/E ratio 55.9 x 81.7 x 189 x 64 x -6.85 x 41.1 x 34.5 x 31.9 x
Yield 0.53% 0.37% 0.14% 0.46% 0.51% 0.69% 0.81% 1.17%
Capitalization / Revenue 14.5 x 18.8 x 45.1 x 7.8 x 7.51 x 6.38 x 5.86 x 5.53 x
EV / Revenue 14.1 x 18.1 x 46.2 x 8.3 x 7.86 x 6.53 x 5.82 x 5.34 x
EV / EBITDA 35.5 x 49.6 x 120 x 25.6 x 24.3 x 19.7 x 17.2 x 15.5 x
EV / FCF 52.8 x 66.9 x 246 x 54.6 x 42.8 x 29.4 x 26.3 x 23 x
FCF Yield 1.89% 1.49% 0.41% 1.83% 2.33% 3.4% 3.8% 4.35%
Price to Book 11.9 x 11.6 x 4.95 x 1.51 x 2.07 x 1.76 x 1.71 x 1.7 x
Nbr of stocks (in thousands) 108,551 108,551 135,395 135,395 135,395 135,395 - -
Reference price 2 197.5 215.8 560.0 186.2 194.7 170.8 170.8 170.8
Announcement Date 2/6/20 2/10/21 2/16/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,480 1,246 1,681 3,234 3,512 3,627 3,945 4,179
EBITDA 1 587 454 645 1,050 1,136 1,204 1,333 1,435
EBIT 1 487.9 370 536.4 654 -3,589 788 913.2 1,003
Operating Margin 32.97% 29.7% 31.91% 20.22% -102.19% 21.73% 23.15% 24.01%
Earnings before Tax (EBT) 1 492.7 366.2 460 537 -3,712 721.1 865.1 946.1
Net income 1 382.8 288 341 394 -3,851 563 669.7 726.2
Net margin 25.86% 23.11% 20.28% 12.18% -109.65% 15.52% 16.97% 17.38%
EPS 2 3.530 2.640 2.970 2.910 -28.44 4.154 4.946 5.361
Free Cash Flow 1 394.2 336.4 315.8 492 644 805.3 873.7 970.3
FCF margin 26.64% 27% 18.78% 15.21% 18.34% 22.21% 22.14% 23.22%
FCF Conversion (EBITDA) 67.16% 74.09% 48.96% 46.86% 56.69% 66.9% 65.56% 67.6%
FCF Conversion (Net income) 102.99% 116.79% 92.61% 124.87% - 143.04% 130.45% 133.62%
Dividend per Share 2 1.050 0.8000 0.8000 0.8500 1.000 1.183 1.383 2.000
Announcement Date 2/6/20 2/10/21 2/16/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 514 752 829 798 855 854 905 848 904 841 894.4 884.1 953.7 903 970
EBITDA 1 164 228 273 276 273 262 293 287 294 272 293.6 289.9 314.4 307 332
EBIT 1 118.6 133 175 177 168 159 188 179 -4,115 167 188 184.2 208.7 200 225
Operating Margin 23.07% 17.69% 21.11% 22.18% 19.65% 18.62% 20.77% 21.11% -455.2% 19.86% 21.01% 20.84% 21.89% 22.15% 23.2%
Earnings before Tax (EBT) 1 61.31 113 169 149 106 130 135 152 -4,130 143 162.7 166.6 197.4 190 215
Net income 1 32.62 82 130 108 74 100 106 122 -4,179 115 126.5 127.8 151.4 147 167
Net margin 6.35% 10.9% 15.68% 13.53% 8.65% 11.71% 11.71% 14.39% -462.28% 13.67% 14.15% 14.46% 15.88% 16.28% 17.22%
EPS 2 0.2600 0.6000 0.9600 0.8000 0.5500 - 0.7800 0.9000 -30.86 - 0.9100 - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/16/22 4/22/22 7/15/22 10/27/22 2/2/23 4/21/23 7/14/23 10/27/23 2/2/24 4/18/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 1,852 1,647 1,228 564 - -
Net Cash position 1 614 911 - - - - 150 816
Leverage (Debt/EBITDA) - - 2.872 x 1.569 x 1.081 x 0.4685 x - -
Free Cash Flow 1 394 336 316 492 644 805 874 970
ROE (net income / shareholders' equity) 22.8% 15.1% 3.93% 2.46% 3.05% 4.03% 4.77% 5.63%
ROA (Net income/ Total Assets) 20% 12.9% 3.14% 1.97% 2.43% 3.1% 3.9% 4.6%
Assets 1 1,919 2,231 10,867 19,990 -158,158 18,161 17,172 15,786
Book Value Per Share 2 16.50 18.50 113.0 124.0 94.20 97.10 99.60 100.0
Cash Flow per Share 3.800 3.280 - - - - - -
Capex 1 87.1 20.1 68.5 83 113 102 111 89
Capex / Sales 5.89% 1.61% 4.08% 2.57% 3.22% 2.81% 2.81% 2.13%
Announcement Date 2/6/20 2/10/21 2/16/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Vitrolife AB

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
170.8 SEK
Average target price
231.7 SEK
Spread / Average Target
+35.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
VITROLIFE AB Stock Vitrolife AB
-12.69% 2.21B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-21.94% 6.7B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+7.08% 5.66B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+28.32% 5.51B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-23.59% 3.56B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+4.75% 2.55B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+30.36% 2.26B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-66.49% 2.24B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-23.20% 1.52B
SANSURE BIOTECH INC. Stock Sansure Biotech Inc.
-12.12% 1.33B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. VITR Stock
  4. Financials Vitrolife AB